IQVIA Holdings Inc. (IQV)
Summary
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
IQVIA Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 30,532 | $6.14M | $6.97M | $827,799.67 | 13.48% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 136 | $29,650.08 | $31,962.72 | $2,312.64 | 7.8% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,609 | $261,992.75 | $378,147.19 | $116,154.44 | 44.33% |
 Curtis Ellergodt Rothschild Investment LLC | 441 | $99,375.23 | $100,636.2 | $1,260.97 | 1.27% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 28,069 | $5.42M | $6.7M | $1.28M | 23.54% |
IQVIA Holdings Inc. (IQV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IQVIA Holdings Inc. ever had a stock split?
IQVIA Holdings Inc. Profile
| Professional Services Industry | Industrials Sector | Ari Bousbib CEO | NYSE Exchange | 46266C105 CUSIP |
| US Country | 94,000 Employees | - Last Dividend | - Last Split | 9 May 2013 IPO Date |
Overview
IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.
Products and Services
- Technology & Analytics Solutions
- Research & Development Solutions
- Contract Sales & Medical Solutions
This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.
This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.
Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.
